Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Date
01/04/23
Title
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in Cookie Settings.